Iris De Bruijn, PhD

Associate Vice President
Sanofi Pasteur

Disclosure: Sanofi Pasteur (Individual(s) Involved: Self): Employee

Presentation(s):

• 160 - Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age

  Oral Abstract